Connecta Therapeutics Raises €3.1 Million
Connecta Therapeutics, a Barcelona-based biopharmaceutical company focused on developing therapies for neurological disorders, has successfully raised €3.1 million in its latest funding round. The round was led by Clave Capital, with additional participation from Inveready, CDTI Innvierte, and the Prous Institute for Biomedical Research.
Leadership and Vision
The company is co-founded by Jordi Fabrega, who serves as CEO, and Josep Prous, the Chief Scientific Officer. Both founders bring a wealth of experience to Connecta Therapeutics, with a shared vision of advancing treatments for complex neurological conditions.
Use of Funds
While specific plans for the newly acquired funds have not been disclosed, it is expected that the investment will support the company's ongoing research and development efforts. Connecta Therapeutics is likely to channel resources into advancing its pipeline of drug candidates aimed at addressing unmet needs in the treatment of neurological disorders.
Investor Insights
Clave Capital's involvement as the lead investor underscores the confidence in Connecta Therapeutics' approach and potential impact in the biopharmaceutical field. The participation of established entities like Inveready and the Prous Institute further validates the company's mission and progress.
Connecta Therapeutics continues to position itself as a key player in the development of innovative therapies for neurological disorders, leveraging this latest funding to accelerate its research and development initiatives.